Online Exclusives

Online Exclusives

Socioeconomic Factors May Impact Multiple Myeloma Survival

A study found that two specific socioeconomic factors – household income and education level – play an important role in long-term survival among patients...

Clinical Trial of Investigational Multiple Myeloma Drug BI-505 Placed on Hold

A phase II study evaluating the investigational agent BI-505 for patients with multiple myeloma (MM) was placed on full clinical hold by the U.S....

Manufacturer of Blinatumomab Seeks Expanded U.S. FDA Approval for Pediatric ALL

A supplemental biologics license application has been submitted to the U.S. Food and Drug Administration (FDA) to expand blinatumomab’s approval to include the treatment...

Europe’s CHMP Recommends Ixazomib for Multiple Myeloma

Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended approval for ixazomib in combination with lenalidomide and dexamethasone for patients with multiple myeloma...

Conference Coverage: Updates on Idelalisib in CLL and FL: Superior PFS and Durable Responses

CHICAGO—Two posters presented at the 2015 ASCO Annual Meeting provided encouraging data for the use of the pi3k delta inhibitor idelalisib in the treatment...

European Commission Approves Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma

The European Commission approved lenalidomide for the treatment of adult patients with relapsed/refractory mantle cell lymphoma (MCL), following a recommendation earlier this year from...

National Institutes of Health Funds Study of Zika Virus Exposure in Olympic Athletes

The National Institutes of Health’s (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is funding a research initiative to...

FDA Grants Fast-Track Designation to Tazemetostat for DLBCL

The U.S. Food and Drug Administration granted fast-track designation to tazemetostat for patients with relapsed/refractory diffuse large B-cell lymphoma with EZH2-activating mutations. Tazemetostat is...

Letermovir Meets Primary Endpoint in Phase III Trial for Cytomegalovirus Prevention

In a global, multicenter, randomized, placebo-controlled, phase III clinical trial evaluating the safety and efficacy of letermovir, the investigational antiviral medication prevented clinically significant...

From ASH 2014: Promising Phase 2 Results with ACE-536 in β-Thalassemia

SAN FRANCISCO — ACE-536, a recombinant fusion protein containing modified activin receptor type IIB and IgG Fc, has shown promising results in the treatment...
Advertisement

Current Issue

December 2021 Volume 7 Issue 15

This issue explores doctor deserts, celebrates the 50th anniversary of the National Cancer Act, and more.

Block title